Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
47 hedge funds and large institutions have $29.9M invested in Merrimack Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 37 reducing their positions, and 7 closing their positions.
88% more call options, than puts
Call options by funds: $214K | Put options by funds: $114K
1.09% more ownership
Funds ownership: 48.35% → 49.44% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 50 → 47 (-3)
24% less capital invested
Capital invested by funds: $39.2M → $29.9M (-$9.31M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
84% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$1.15M |
| 2 |
LA
LVW Advisors
Pittsford,
New York
|
+$342K |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$244K |
| 4 |
CCIA
Campbell & Co Investment Adviser
Baltimore,
Maryland
|
+$123K |
| 5 |
Morgan Stanley
New York
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$2.87M |
| 2 |
NM
Newtyn Management
New York
|
-$1.84M |
| 3 |
2L
22NW LP
Seattle,
Washington
|
-$1.68M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$990K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$455K |
MACK Hedge Fund Activity: Q3 2019 in Review
47 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2019, worth a combined $29.9M — down 24% from $39.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MACK and 4 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 6 added.
The largest buyer was Sepio Capital, opening a new position worth an estimated $1.15M. The largest seller was Nuveen, exiting entirely with an estimated $2.87M sold.
- 47 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2019, down from 50 in Q2 2019.
- Funds reported $29.9M of Merrimack Pharmaceuticals, Inc. stock for Q3 2019, down 24% quarter-over-quarter.
- 4 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2019 and 7 closed out, a net change of -3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2019 was Sepio Capital, an estimated $1.15M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2019 was Nuveen, an estimated $2.87M sold.
Based on aggregated 13F filings for Q3 2019.